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AIM
The overall aim of the project was to develop an evidence-
based clinical practice guideline for management of anemia
and chronic kidney disease (CKD). The guideline consists of
recommendations, rationale statements and a summary of
systematically generated evidence on relevant predefined
clinical topics.
OVERVIEW PROCESS
Guideline development process included the following
sequential and concurrent steps:
K Appointing Work Group members and Evidence Review
Team (ERT).
K Discussing process, methods, and results.
K Developing and refining topics.
K Identifying populations, interventions or predictors, and
outcomes of interest.
K Selecting topics for systematic evidence review.
K Standardizing quality assessment methodology.
K Developing and implementing literature search strategies.
K Screening abstracts and retrieving full text articles based
on predefined eligibility criteria.
K Creating data extraction forms.
K Data extracting and performing critical appraisal of the
literature.
K Grading the methodology and outcomes in individual
studies.
K Tabulating data from individual studies into summary
tables.
K Grading quality of evidence for each outcome across
studies, and assessing the overall quality of evidence
across outcomes with the aid of evidence profiles.
K Grading the strength of recommendations based on the
quality of evidence and other considerations.
K Finalizing guideline recommendations and supporting
rationale statements.
K Sending the guideline draft for peer review to the KDIGO
Board of Directors in June 2011, and for public review in
September 2011.
K Publishing the final version of the guideline.
The Work Group, KDIGO Co-Chairs, ERT, and KDIGO
support staff met for two 2-day meetings for training in the
guideline development process, topic discussion, and con-
sensus development.
Commissioning of work group and evidence review team
KDIGO Co-Chairs appointed the Work Group Co-chairs.
Work Group Co-Chairs then assembled the Work Group
consisting of domain experts, including individuals with
expertise in internal medicine, adult and pediatric nephrol-
ogy, cardiology, hematology, oncology, hypertension, pathol-
ogy, pharmacology, epidemiology and endocrinology. Tufts
Center for Kidney Disease Guideline Development and
Implementation at Tufts Medical Center in Boston, Massa-
chusetts, USA was contracted to conduct systematic evidence
review and provide expertise in guideline development
methodology. The ERT consisted of physician-methodolo-
gists with expertise in nephrology, a project coordinator and
manager, and a research assistant. The ERT instructed and
advised Work Group members in all steps of literature
review, critical literature appraisal, and guideline develop-
ment. The Work Group and the ERT collaborated closely
throughout the project.
Defining scope and topics
Work Group Co-Chairs first defined the overall scope and
goals of the guideline. Work Group Co-Chairs then drafted a
preliminary list of topics and key clinical questions. In light
of new evidence, it was decided that an update of the topics
presented in the 2006 and 2007 KDOQI guidelines would be
the best approach. The Work Group and ERT further
developed and refined each topic, specified screening criteria,
literature search strategies, and data extraction forms
(Table 8).
Establishing the process for guideline development
The ERT performed literature searches, organized abstract
and article screening. The ERT also coordinated the
methodological and analytic process of the report, defined
and standardized the methodology of performing literature
searches, data extraction, and summarizing the evidence.
Throughout the project, the ERT offered suggestions for
guideline development, led discussions on systematic review,
literature searches, data extraction, assessment of quality and
applicability of articles, evidence synthesis, grading of
evidence and guideline recommendations, and consensus
development. The Work Group took the primary role of
writing the guidelines and rationale statements and retained
final responsibility for the content of the guideline statements
and the accompanying narrative.
The Work Group Co-Chairs prepared the first draft of the
scope of work document as a series of topics to be considered
by Work Group members. The scope of work document was
based primarily on the existing KDOQI guidelines on
anemia. At their first two-day meeting, Work Group
members revised the initial working document to include
all topics of interest to the Work Group. The inclusive,
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combined set of questions formed the basis for the
deliberation and discussion that followed. The Work Group
strove to ensure that all topics deemed clinically relevant and
worthy of review were identified and addressed.
Formulating questions of interest
Questions of interest were formulated according to the
PICODD (Population, Intervention, Comparator, Outcome,
study Design and Duration of follow up) criteria. Details of
the PICODD criteria are presented in Table 8.
Ranking of outcomes
The Work Group ranked outcomes of interest based on their
importance for informing clinical decision making (Table 9).
Mortality, cardiovascular mortality, cardiovascular events and
ESRD outcomes were graded as ‘critical,’ transfusion and
QoL outcomes were graded as ‘high,’ and all other outcomes
were graded as ‘moderate.’
Literature searches and article selection
The Work Group sought to build on the evidence base and
topics addressed in the previous Kidney Disease Outcomes
Quality Initiative (KDOQI) clinical practice guidelines and
clinical practice recommendations for anemia in chronic
kidney disease in 2006 as well as the KDOQI clinical practice
guidelines and clinical practice recommendations for anemia
in chronic kidney disease 2007 update of hemoglobin target.
Modules were created for randomized controlled trials
(RCTs), kidney disease, anemia, and erythropoietin, transfu-
sion, iron deficiency, and adjuvant search terms. The search
terms were then limited to years 2006–2010 for studies related
to anemia interventions. For transfusion the literature search
was conducted from 1989–2010. A separate search was run
for observational studies on iron overload and hemoglobin
status as predictors for clinical outcomes (See Appendix 1
online).
The searches were run in MEDLINE, Cochrane Central
Register of Controlled Clinical Trials and Cochrane Database
of Systematic Reviews. The initial search for RCTs was
conducted in April 2010 and subsequently updated in
October of 2010. The search for observational studies was
later conducted in September 2010. The search yield was also
supplemented by articles provided by Work Group members
through March 2012. MEDLINE search results were screened
by members of the ERT for relevance using pre-defined
eligibility criteria.
The total yield from the search was 4,334 abstracts for
RCTs and 3,717 abstracts for observational studies. Fifty-six
abstracts and 53 full texts from RCTs were accepted and 97
abstracts and 21 full texts from observational studies were
Table 8 | Systematic review topics and screening criteria
Identifying why, when and which patients to treat for anemia and iron deficiency
Population All CKD stages for longitudinal, cross-sectional or RCTs. Any population for systematic reviews
Intervention RBC transfusion, Iron (all forms, routes of administration, dosages), ESA (all forms, dosages, targets, protocols, schedules, etc),
pharmacological and non-pharmacological adjuvants to ESA, Hb or iron status
Comparator Other interventions, ‘‘no’’ interventions, different forms, routes of administration, dosages, targets, protocols, schedules, etc.
Outcomes All-cause mortality, Cardiovascular events, ESRD, Quality of life, Progression of kidney disease, Transfusions, Major symptoms
Study design RCTs, Large longitudinal (prospective or retrospective) observational studies or cross sectional studies with multivariate analyses
NZ50 per arm
Evaluating anemia treatment, including treatment resistance
Population Adults and children with CKD, any stage and any comorbidity (including cancer, CVD, etc.)
Intervention RBC transfusions; Iron (all forms, routes of administration, dosages), ESA (all forms, dosages, targets, protocols, etc), pharmacological
and non-pharmacological adjuvants to ESA including L-carnitine, vitamin C, androgens, pentoxifylline; other interventions used to
treat or enhance the treatment of anemia or anemia-related symptoms
Comparator Other interventions, ‘‘no’’ interventions, different forms, routes of administration, dosages, targets, protocols, schedules, etc.
Outcomes Death, Cardiac events, Stroke, CKD progression, Quality of life, Thromboembolic events, Pulmonary embolism, Symptomatic deep
vein thrombosis, Loss of vascular access, Transfusion requirements, Cognitive function, Sexual function, Other similar quality of life
measures, Objective physical function tests, Infections, Loss of transplant eligibility due to antibody sensitization, Antibody
sensitization, New cancer or progression of existing cancer, Seizure, Other clinically important adverse events, ESA dose: for
comparisons of different ESA regimens and for iron and adjuvant interventions, Achieved Hb/Hb variability for comparisons of
different ESA regimens and for iron and adjuvant interventions
Study Design RCTs
NZ50 per arm
Minimum follow-up duration: 6 months
CKD, chronic kidney disease; CVD, cardiovascular disease; ESA, erythropoiesis-stimulating agent; ESRD, end-stage renal disease; Hb, hemoglobin; RBC, red blood cell;
RCT, randomized controlled trial.
Table 9 | Hierarchy of importance of outcomes
Hierarchya Outcomesb
Critical importance Mortality, Cardiovascular mortality, Cardiovascular
events, ESRD
High importance Transfusion, Quality of life
Moderate
importance
Hb (categorical and continuous), ESA dose
(categorical and continuous), adverse events
ESA, erythropoiesis-stimulating agent; ESRD, end-stage renal disease; Hb, hemo-
globin.
aOutcomes of lesser importance are excluded from review.
bThis categorization was the consensus of the Work Group for the purposes of this
guideline only. The lists are not meant to reflect outcome ranking for other areas of
kidney disease management. The Work Group acknowledges that not all clinicians,
patients or families, or societies would rank all outcomes the same.
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accepted. Journal articles reporting original data, meta-
analyses or systematic reviews were selected for evidence
review. Editorials, letters, abstracts, unpublished reports and
articles published in non-peer reviewed journals were not
included. The Work Group also decided to exclude publica-
tions from journal supplements because of potential
differences in the process of how they get solicited, selected,
reviewed and edited compared to peer-reviewed publications.
The overall search yield along with the number of abstracts
identified and articles reviewed is presented in Table 10.
Data extraction
Fifty-three full text articles from RCTs were extracted by the
ERT. The ERT, in consultation with the Work Group,
designed forms to capture data on design, methodology,
sample characteristics, interventions, comparators, outcomes,
results and limitations of individual studies. Methodology
and outcomes were also systematically graded (see the section
on grading below) and recorded during the data extraction
process.
Summary tables
Summary tables were developed for each comparison of
interest. Studies included in the evidence base for the KDOQI
clinical practice guidelines on Anemia in CKD and update of
hemoglobin target were also incorporated if they fulfilled the
inclusion criteria for the current guideline.
Summary tables contain outcomes of interest, relevant
population characteristics, description of intervention and
comparator, results, and quality grading for each outcome.
Categorical and continuous outcomes were summarized
separately. Work Group members proofed all summary
table data and quality assessments. Summary tables will
be available at www.kdigo.org/clinical_practice_guidelines/
anemia.php.
Evidence profiles
Evidence profiles were constructed to assess and record
quality grading and description of effect for each outcome
across studies, and quality of overall evidence and description
of net benefits or harms of intervention or comparator across
all outcomes. These profiles aim to make the evidence
synthesis process transparent. Decisions in the evidence
profiles were based on data from the primary studies listed in
corresponding summary tables, and on judgments of the ERT
and the Work Group. When the body of evidence for a
particular comparison of interest consisted of only one study,
the summary table provided the final level of synthesis and
evidence profile was not generated. Each evidence profile was
initially constructed by the ERT and then reviewed, edited
and approved by the Work Group.
Grading of quality of evidence for outcomes of
individual studies
Methodological quality. Methodological quality (internal
validity) refers to the design, conduct, and reporting of
outcomes of a clinical study. Previously devised three-level
classification system for quality assessment was used to grade
the overall study quality and quality for all relevant outcomes
in the study (Table 11). Variations of this system have
been used in most KDOQI and all KDIGO guidelines
and have been recommended for the US Agency for
Healthcare Research and Quality Evidence-based Practice
Center program (http://effectivehealthcare.ahrq.gov/repFiles/
2007_10DraftMethodsGuide.pdf).
Each study was given an overall quality grade based on its
design, methodology (randomization, allocation, blinding,
definition of outcomes, appropriate use of statistical methods
etc), conduct (drop-out percentage, outcome assessment
methodologies, etc) and reporting (internal consistency,
clarity, thoroughness/precision, etc). Each reported outcome
was then evaluated and given an individual grade depending
on the quality of reporting and methodological issues specific
to that outcome. However, the quality grade of an individual
outcome could not exceed the quality grade for the overall
study.
Rating the quality of evidence and the strength of
guideline recommendations
A structured approach, based on GRADE241–243 and facili-
tated by the use of evidence profiles was used in order to
grade the quality of the overall evidence and the strength of
recommendations. For each topic, the discussion on grading
of the quality of the evidence was led by the ERT, and the
discussion regarding the strength of the recommendations
was led by the Work Group Chairs. The ‘strength of a
recommendation’ indicates the extent to which one can be
Table 10 | Literature search yield of primary articles for systematic review topics
Total abstracts from updated search Abstracts accepted Full text accepted Full text extracted Articles in summary tables
4,334 RCT 56 53 53 31
3,717 Observational 97 21 21 21
RCT, randomized controlled trial.
Table 11 | Classification of study quality
Good
quality
Low risk of bias and no obvious reporting errors, complete
reporting of data. Must be prospective. If study of
intervention, must be randomized controlled study (RCT).
Fair
quality
Moderate risk of bias, but problems with study/paper are
unlikely to cause major bias. If study of intervention, must
be prospective.
Poor
quality
High risk of bias or cannot exclude possible significant biases.
Poor methods, incomplete data, reporting errors. Prospective
or retrospective.
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confident that adherence to the recommendation will do
more good than harm. The ‘quality of a body of evidence’
refers to the extent to which our confidence in an estimate of
effect is sufficient to support a particular recommenda-
tion.242
Grading the quality of evidence for each outcome
Following GRADE, the quality of a body of evidence
pertaining to a particular outcome of interest was initially
categorized based on study design. For questions of
interventions, the initial quality grade was ‘High’ when the
body of evidence consisted of randomized controlled trials;
‘Low’, if it consisted of observational studies; or ‘Very Low’, if
it consisted of studies of other study designs. For questions of
interventions, the Work Group decided to use only
randomized controlled trials. The grade for the quality of
evidence for each intervention/outcome pair was then
lowered if there were serious limitations to the methodolo-
gical quality of the aggregate of studies, if there were
important inconsistencies in the results across studies, if there
was uncertainty about the directness of evidence including
limited applicability of the findings to the population of
interest, if the data were imprecise (a low event rate [0 or 1
event] in either arm or confidence interval spanning a range
o0.5 to42.0) or sparse (only 1 study or total No100), or if
there was thought to be a high likelihood of bias. The final
grade for the quality of the evidence for an intervention/
outcome pair could be one of the following four grades:
‘High’, ‘Moderate’, ‘Low’ or ‘Very Low’ (Table 12).
Grading the overall quality of evidence
The quality of the overall body of evidence was then
determined based on the quality grades for all outcomes of
interest, taking into account explicit judgments about the
relative importance of each outcome. The resulting four final
categories for the quality of overall evidence were: ‘A’, ‘B’, ‘C’
or ‘D’ (Table 13).
Assessment of the net health benefit across all important
clinical outcomes
The net health benefit was determined based on the anticipated
balance of benefits and harms across all clinically important
outcomes (Table 14). The assessment of net benefit was affected
by the judgment of the Work Group and the ERT.
Grading the strength of the recommendations
The strength of a recommendation is graded as Level 1 or
Level 2. Table 15 shows the KDIGO nomenclature for grading
the strength of a recommendation and the implications of each
level for patients, clinicians and policy makers. Recommenda-
tions can be for or against doing something. Table 16 shows
that the strength of a recommendation is determined not just
by the quality of the evidence, but also by other, often complex
judgments regarding the size of the net medical benefit, values
and preferences, and costs. Formal decision analyses including
cost analysis were not conducted.
Table 12 | GRADE system for grading quality of evidence
Step 1: Starting grade for
quality of evidence based
on study design Step 2: Reduce grade Step 3: Raise grade
Final grade for quality of evidence and
definition
Randomized trials = High
Observational study = Low
Any other evidence = Very
low
Study quality
1 level if serious limitations
2 levels if very serious limitations
Consistency
1 level if important inconsistency
Directness
1 level if some uncertainty
2 levels if major uncertainty
Other
1 level if sparse or imprecise datac
1 level if high probability of
reporting bias
Strength of association
+1 level is stronga,
no plausible confounders
+2 levels if very strongb,
no major threats to validity
Other
+1 level if evidence of a
dose-response gradient
+1 level if all residual plausible
confounders would have
reduced the observed effect
High = Further research is unlikely to change
confidence in the estimate of the effect
Moderate = Further research is likely to have
an important impact on confidence in the
estimate of effect, and may change the
estimate
Low = Further research is very likely to have an
important impact on confidence in the
estimate, and may change the estimate
Very low = Any estimate of effect is very
uncertain
GRADE, Grading of Recommendations Assessment, Development, and Evaluation.
aStrong evidence of association is defined as ‘significant relative risk of42 (o0.5)’ based on consistent evidence from two or more observational studies, with no plausible
confounders.
bVery strong evidence of association is defined as ‘significant relative risk of 45 (o0.2)’ based on direct evidence with no major threats to validity.
cSparse if there is only one study or if total No100. Imprecise if there is a low event rate (0 or 1 event) in either arm or confidence interval spanning a rangeo0.5 to42.0.
Adapted by permission from Macmillan Publishers Ltd: Kidney International. Uhlig K, Macleod A, Craig J et al. Grading evidence and recommendations for clinical practice
guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 70: 2058–2065;243 accessed http://
www.nature.com/ki/journal/v70/n12/pdf/5001875a.pdf
Table 13 | Final grade for overall quality of evidence
Grade
Quality of
evidence Meaning
A High We are confident that the true effect lies close to that
of the estimate of the effect.
B Moderate The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is
substantially different.
C Low The true effect may be substantially different from
the estimate of the effect.
D Very low The estimate of effect is very uncertain, and often will
be far from the truth.
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Ungraded statements
This category was designed to allow the Work Group to
issue general advice. Typically an ungraded statement
meets the following criteria: it provides guidance based
on common sense; it provides reminders of the obvious;
it is not sufficiently specific to allow application of evidence
to the issue and therefore it is not based on systematic
evidence review. Common examples include recommenda-
tions about frequency of testing, referral to specialists, and
routine medical care. We strove to minimize the use of
ungraded recommendations.
This grading scheme with two levels for the strength
of a recommendation together with four levels of grading
the quality of the evidence, and the option of an ungraded
statement for general guidance was adopted by the
KDIGO Board in December 2008. The Work Group took
the primary role of writing the recommendations and
rationale statements and retained final responsibility for the
content of the guideline statements and the accompanying
narrative. The ERT reviewed draft recommendations and
grades for consistency with the conclusions of the evidence
review.
Format for guideline recommendations
Each chapter contains one or more specific recommenda-
tions. Within each recommendation, the strength of
recommendation is indicated as level 1 or level 2 and the
quality of the supporting evidence is shown as A, B, C or D.
These are followed by a brief background with relevant
definitions of terms and the rationale summarizing the key
points of the evidence base and narrative supporting the
recommendation. Where appropriate, research recommenda-
tions are suggested for future research to resolve current
uncertainties.
Limitations of approach
While the literature searches were intended to be compre-
hensive, they were not exhaustive. MEDLINE was the only
database searched. Hand searches of journals were not
performed, and review articles and textbook chapters were
Table 14 | Balance of benefits and harm
When there was evidence to determine the balance of medical benefits and harm of an intervention to a patient, conclusions were categorized as
follows:
K For statistically significant benefit/harm report as ‘Benefit/Harm of Drug X’.
K For non-statistically significant benefit/harm, report as ‘Possible benefit/harm of Drug X’.
K In instances where studies are inconsistent, report as ‘Possible benefit/harm of Drug X’.
K ‘No difference’ can only be reported if a study is not imprecise.
K ‘Insufficient evidence’ if imprecision is a factor.
Table 15 | KDIGO nomenclature and description for grading recommendations
Grade*
Implications
Patients Clinicians Policy
Level 1
‘We recommend’
Most people in your situation would want
the recommended course of action and
only a small proportion would not.
Most patients should receive the
recommended course of action.
The recommendation can be evaluated
as a candidate for developing a policy
or a performance measure.
Level 2
‘We suggest’
The majority of people in your situation
would want the recommended course of
action, but many would not.
Different choices will be appropriate for
different patients. Each patient needs help
to arrive at a management decision
consistent with her or his values and
preferences.
The recommendation is likely to
require substantial debate and
involvement of stakeholders before
policy can be determined.
*The additional category ‘Not Graded’ was used, typically, to provide guidance based on common sense or where the topic does not allow adequate application of evidence.
The most common examples include recommendations regarding monitoring intervals, counseling, and referral to other clinical specialists. The ungraded recommendations
are generally written as simple declarative statements, but are not meant to be interpreted as being stronger recommendations than Level 1 or 2 recommendations.
Table 16 | Determinants of strength of recommendation
Factor Comment
Balance between desirable and
undesirable effects
The larger the difference between the desirable and undesirable effects, the more likely a strong
recommendation is warranted. The narrower the gradient, the more likely a weak recommendation is warranted.
Quality of the evidence The higher the quality of evidence, the more likely a strong recommendation is warranted.
Values and preferences The more variability in values and preferences, or more uncertainty in values and preferences, the more
likely a weak recommendation is warranted.
Costs (resource allocation) The higher the costs of an intervention—that is, the more resources consumed—the less likely a strong
recommendation is warranted.
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Table 17 | The Conference on Guideline Standardization (COGS) checklist245 for reporting clinical practice guidelines
Topic Description Discussed in KDIGO Anemia Guideline
1. Overview material Provide a structured abstract that includes the
guideline’s release date, status (original, revised,
updated), and print and electronic sources.
Abstract and Methods for Guideline Development.
2. Focus Describe the primary disease/condition and intervention/
service/technology that the guideline addresses. Indicate
any alternative preventative, diagnostic or therapeutic
interventions that were considered during development.
Management of adults and children with CKD and kidney
transplant recipients at risk for or with anemia.
3. Goal Describe the goal that following the guideline is expected
to achieve, including the rationale for development of a
guideline on this topic.
This clinical practice guideline is intended to assist the
practitioner caring for patients with CKD and anemia and to
prevent deaths, cardiovascular disease events and progression
to kidney failure while optimizing patients’ quality of life.
4. User/setting Describe the intended users of the guideline (e.g. provider
types, patients) and the settings in which the guideline is
intended to be used.
Providers: Nephrologists (adult and pediatric), Dialysis providers
(including nurses), Internists, and Pediatricians.
Patients: Adult and children with CKD at risk for or with anemia.
Policy Makers: Those in related health fields.
5. Target population Describe the patient population eligible for guideline
recommendations and list any exclusion criteria.
CKD individuals at risk for or with anemia, adult and children.
6. Developer Identify the organization(s) responsible for guideline
development and the names/credentials/potential conflicts
of interest of individuals involved in the guideline’s
development.
Organization: KDIGO.
7. Funding source/
sponsor
Identify the funding source/sponsor and describe its role in
developing and/or reporting the guideline. Disclose
potential conflict of interest.
KDIGO is supported by the following consortium of sponsors:
Abbott, Amgen, Bayer Schering Pharma, Belo Foundation, Bristol-
Myers Squibb, Chugai Pharmaceutical, Coca-Cola Company, Dole
Food Company, Fresenius Medical Care, Genzyme, Hoffmann-
LaRoche, JC Penney, Kyowa Hakko Kirin, NATCO—The
Organization for Transplant Professionals, NKF-Board of Directors,
Novartis, Pharmacosmos, PUMC Pharmaceutical, Robert and Jane
Cizik Foundation, Shire, Takeda Pharmaceutical, Transwestern
Commercial Services, Vifor Pharma, and Wyeth. No funding is
accepted for the development or reporting of specific guidelines.
All stakeholders could participate in open review.
Refer to Work Group Financial Disclosures.
8. Evidence collection Describe the methods used to search the scientific
literature, including the range of dates and databases
searched, and criteria applied to filter the retrieved
evidence.
Modules were created for randomized controlled trials (RCTs),
kidney disease, anemia, and erythropoietin, transfusion, iron
deficiency, and adjuvant search terms. The search terms were
then limited to years 2006–2010 for studies related to anemia
interventions. For transfusion the literature search was
conducted from 1989–2010. A separate search was run for
observational studies on iron overload and hemoglobin status as
predictors for clinical outcomes. See Table 8 for screening
criteria.
Searches were run in MEDLINE, Cochrane Central Register of
Controlled Clinical Trials and Cochrane Database of Systematic
Reviews. The initial search for RCTs was conducted in April 2010
and subsequently updated in October of 2010. The search for
observational studies was later conducted in September 2010.
The search yield was also supplemented by articles provided by
Work Group members through March 2012.
9. Recommendation
grading criteria
Describe the criteria used to rate the quality of evidence
that supports the recommendations and the system for
describing the strength of the recommendations.
Recommendation strength communicates the importance
of adherence to a recommendation and is based on both
the quality of the evidence and the magnitude of
anticipated benefits and harms.
Quality of individual studies was graded in a three-tiered
grading system (see Table 11). Quality of evidence (Table 12)
was graded following the GRADE approach. Strength of the
recommendation was graded in a two-level grading system
which was adapted from GRADE for KDIGO with the
quality of overall evidence graded on a four-tiered system
(Tables 13 and 15).
The Work Group could provide general guidance in ungraded
statements.
10. Method for
synthesizing evidence
Describe how evidence was used to create
recommendations, e.g., evidence tables, meta-analysis,
decision analysis.
For systematic review topics, summary tables and evidence
profiles were generated.
For recommendations on treatment interventions, the steps
outlined by GRADE were followed.
11. Prerelease review Describe how the guideline developer reviewed and/or
tested the guidelines prior to release.
The guideline has undergone internal review by the KDIGO
Board of Directors in June 2011 and external review in
September 2011. Public review comments were compiled and
fed back to the Work Group, which considered comments in its
revision of the guideline.
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not systematically searched. However, important studies
known to domain experts that were missed by the electronic
literature searches were added to retrieved articles and
reviewed by the Work Group.
Summary of the methodological review process
Several tools and checklists have been developed to assess the
quality of the methodological process for systematic
review and guideline development. These include the
Appraisal of Guidelines for Research and Evaluation
(AGREE) criteria,244 the Conference on Guideline Standar-
dization (COGS) checklist,245 and the Institute of Medicine’s
recent Standards for Systematic Reviews246 and Clinical
Practice Guidelines We Can Trust.247 Table 17 and Appendix
2 online show, respectively, the COGS criteria which
correspond to the AGREE checklist and the Institute of
Medicine standards, and how each one of them is addressed
in this guideline.
SUPPLEMENTARY MATERIAL
Appendix 1: Online search strategies.
Appendix 2: Concurrence with Institute of Medicine standards for
systematic reviews and for guidelines.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/anemia.php
Table 17 | Continued
Topic Description Discussed in KDIGO Anemia Guideline
12. Update plan State whether or not there is a plan to update the
guideline and, if applicable, expiration date for this
version of the guideline.
There is no date set for updating. The need for updating of the
guideline will depend on the publication of new evidence that
would change the quality of the evidence or the estimates for
the benefits and harms. Results from registered ongoing
studies and other publications will be reviewed periodically
to evaluate their potential to impact on the recommendations
in this guideline.
13. Definitions Define unfamiliar terms and those critical to correct
application of the guideline that might be subject to
misinterpretation.
Abbreviations and Acronyms.
14. Recommendations
and rationale
State the recommended action precisely and the specific
circumstances under which to perform it. Justify each
recommendation by describing the linkage between
the recommendation and its supporting evidence.
Indicate the quality of evidence and the recommendation
strength, based on the criteria described in Topic 9.
Each guideline chapter contains recommendations for
management of CKD patients at risk for or with anemia. Each
recommendation builds on a supporting rationale with evidence
tables if available. The strength of the recommendation and the
quality of evidence are provided in parenthesis within each
recommendation.
15. Potential benefits
and harm
Describe anticipated benefits and potential risks
associated with implementation of guideline
recommendations.
The benefits and harm for each comparison of interventions are
provided in summary tables and summarized in evidence
profiles. The estimated balance between potential benefits and
harm was considered when formulating the recommendations.
16. Patient preferences Describe the role of patient preferences when a
recommendation involves a substantial element of
personal choice or values.
Many recommendations are Level 2 or ‘‘discretionary’’ which
indicates a greater need to help each patient arrive at a
management decision consistent with her or his values and
preferences.
17. Algorithm Provide (when appropriate) a graphical description
of the stages and decisions in clinical care described
by the guideline.
See Chapter 4.
18. Implementation
considerations
Describe anticipated barriers to application of the
recommendations. Provide reference to any auxiliary
documents for providers or patients that are intended
to facilitate implementation. Suggest review criteria for
measuring changes in care when the guideline is
implemented.
These recommendations are global. Review criteria were not
suggested because implementation with prioritization and
development of review criteria have to proceed locally.
Furthermore, most recommendations are discretionary,
requiring substantial discussion among stakeholders before they
can be adopted as review criteria.
Suggestions were provided for future research.
CKD, chronic kidney disease; GRADE, Grading of Recommendations Assessment, Development, and Evaluation; KDIGO, Kidney Disease: Improving Global Outcomes;
RCT, randomized controlled trial.
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